Reata (RETA) - שולי הרווח הגולמי

סמלים רשמיים של חברת Reata Pharma (RETA)

Reata Pharmaceuticals management has successfully completed a merger with a global biotech behemoth, focusing on sales expansion. High barriers to entry in the rare pathology niche create a fierce struggle for monopoly status. The business relies on the drug Skyclarys, which forms a closed therapy ecosystem. Tracking the consolidated gross margin on GURU.Markets, we note that 91.60 determines this parameter level.

RETA (Reata) היסטוריית שולי רווח גולמי מ-04.07.2022 עד 07.10.2023

פילוחי מדדים מקיפים ואנליטיקה עבור Reata (RETA)

- מחיר שוק ויעדי מחיר של אנליסטים:
הערכת שווי פונדמנטלית:Reata Pharmaceuticals
מוצר המיוצר על ידי Reata Pharmaceuticals Inc

The outsourcing model of Reata Pharmaceuticals shifts production to external contractors, making the control of direct costs critically important. The gross margin, equal to 91.60, measures the profit share after deducting the cost of goods sold, reflecting the efficiency of contract management. Steady growth of this ratio confirms operational resilience, while any anomalies in the target gross margin signal risks of reporting manipulation.